Australian and New Zealand Living Guideline cholesterol-lowering therapy for people with chronic kidney disease (CARI Guidelines): Reducing the evidence-practice gap.

MLA

Cashmore, Brydee, et al. “Australian and New Zealand Living Guideline Cholesterol-Lowering Therapy for People with Chronic Kidney Disease (CARI Guidelines): Reducing the Evidence-Practice Gap.” Nephrology (Carlton, Vic.), vol. 29, no. 8, Aug. 2024, pp. 495–509. EBSCOhost, https://doi.org/10.1111/nep.14295.

APA

Cashmore, B., Tunnicliffe, D. J., Palmer, S., Blythen, L., Boag, J., Kostner, K., Krishnasamy, R., Lambert, K., Miller, A., Mullan, J., Patu, M., Phoon, R. K. S., Rix, L., Trompf, N., Johnson, D. W., & Walker, R. (2024). Australian and New Zealand Living Guideline cholesterol-lowering therapy for people with chronic kidney disease (CARI Guidelines): Reducing the evidence-practice gap. Nephrology (Carlton, Vic.), 29(8), 495–509. https://doi.org/10.1111/nep.14295

Chicago

Cashmore, Brydee, David J Tunnicliffe, Suetonia Palmer, Llyod Blythen, Jane Boag, Karam Kostner, Rathika Krishnasamy, et al. 2024. “Australian and New Zealand Living Guideline Cholesterol-Lowering Therapy for People with Chronic Kidney Disease (CARI Guidelines): Reducing the Evidence-Practice Gap.” Nephrology (Carlton, Vic.) 29 (8): 495–509. doi:10.1111/nep.14295.